TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05802563

Intervention type: DEVICE
Intervention: fitness tracker
Description: Study subjects will wear a Fitbit fitness tracker

Intervention type: DEVICE
Intervention: fitness tracker
Description: Study subjects will wear a Fitbit fitness tracker
Study: NCT03270163

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Description: The following tests and measurements will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening:~* three simple electrical stimulations,~* three electrical doublets at the frequency of 100Hz~For each type of electrical stimulation, the stimulations will be carried out 3 times and reproduced at 1 hour intervals.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic stimulation
Description: The following tests and measurements will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening:~* three simple magnetic stimulations,~* three magnetic doublets at the frequency of 100Hz~For each type of magnetic stimulation, the stimulations will be carried out 3 times and reproduced at 1 hour intervals.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasound measurement
Description: The ultrasound measurement of the thickness of the quadriceps muscle will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening.
Study: NCT06345118

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Otago exercise program
Description: The OEP consists of 17 strength and balance exercises and a walking program performed thrice a week by the older adult at home.~Program Prescription The program is designed to be delivered over 6 months and includes a minimum of 5 visits. The first visit is Day 1 of Otago when performance of the functional measures is assessed, and the exercises are prescribed at the Rehabilitation Center of the National Geriatric Hospital. Then, the therapist will see the patient for 4 visits over an 8-week period (typically every other week). This is considered the initial bolus of Otago. Then, the therapist will follow the patient via phone calls every week and make a visit at three months, four months, five months, and six months to reassess the patient's training ability and compliance.~Monitoring:~Calendars can be completed each month to document any falls. A calendar or diary can be used to monitor compliance with the exercise programme
Study: NCT06085209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The truFreeze Spray Cryotherapy
Description: A novel FDA cleared technique that allows for liquid nitrogen (LN2) to be delivered in a metered fashion via a catheter through a flexible bronchoscope.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ballon dilation
Description: An endoscopic balloon that is inflated with water to pressures between 45 and 131 psi (3-9 atm) using a syringe and pressure manometer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ballon dilation
Description: An endoscopic balloon that is inflated with water to pressures between 45 and 131 psi (3-9 atm) using a syringe and pressure manometer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radial Incision
Description: Carbon dioxide (CO2) laser or Monopolar electrocautery knife

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial Incision
Description: Carbon dioxide (CO2) laser or Monopolar electrocautery knife
Study: NCT06168578

Intervention type: DEVICE
Intervention: ultrasound
Description: Optic nerve diameter will be measured by ultrasound at certain stages of the operation in Group I (ARM-) and Group II (ARM+)

Intervention type: DEVICE
Intervention: ultrasound
Description: Optic nerve diameter will be measured by ultrasound at certain stages of the operation in Group I (ARM-) and Group II (ARM+)
Study: NCT06054464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC14586
Description: Part 1 and Part 2: Single, oral dose of PC14586 on day 1 and single, oral dose of PC14586 on day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC14586
Description: Part 1 and Part 2: Single, oral dose of PC14586 on day 1 and single, oral dose of PC14586 on day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Part 1: Daily oral dose of rabeprazole on days 11-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Part 2: Twice daily oral dose of famotidine on days 11-13. Single, oral dose of famotidine on day 14.
Study: NCT06469372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac amyloidosis deep learning model
Description: This is a deep learning algorithm which intakes a patient's age, sex, clinical factors known to be related to amyloidosis and their ECG and echocardiogram results and determines their estimated risk for having cardiac amyloidosis.
Study: NCT04782310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 75mg two hour preoperatively, 12 hours postoperative and will continue for one week twice per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 75mg two hour preoperatively, 12 hours postoperative and will continue for one week twice per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine 30mg two hour preoperatively ...will be continued for one week once per day after breakfast .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine 30mg two hour preoperatively ...will be continued for one week once per day after breakfast .
Study: NCT05232149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib( lower dose)
Description: Orelabrutinib is a white, round, uncoated tablet, will be taken lower dose QD by patients with persistent or chronic primary immune thrombocytopenia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib( higher dose)
Description: Orelabrutinib is a white, round, uncoated tablet, will be taken higher dose QD by patients with persistent or chronic primary immune thrombocytopenia
Study: NCT05993195

Intervention type: DEVICE
Intervention: Conduit Titanium Interbody Graft
Description: The Concorde Bullet Device is compared with Conduit Titanium Interbody Graft for lumber fusion in terms of reoperation rates at 2 years.

Intervention type: DEVICE
Intervention: Concorde Bullet Device
Description: This traditional device is to compare the clinical results of the new Conduit Titanium Interbody device for lumbar fusion
Study: NCT05760937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986447
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT04916197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine prolonged sedation
Description: Dexmedetomidine for 24h after patients finished endovascular thrombectomy and returned to ICU.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: An equal dose of 0.9% saline 24h after patients finished endovascular thrombectomy and returned to ICU.
Study: NCT06211348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genomic Sequencing
Description: Individuals who request prenatal diagnostic testing with standard chromosomal microarray will be offered genomic sequencing (GS) as an option to assess for additional disease risk.
Study: NCT06141408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MPowerment Stigma-reduction Intervention
Description: In-person events will focus on five specific goals: Fostering a sense of community acceptance and social connection among Black sexual minority men (BSMM), promoting self-acceptance of sexual identity, teaching skills for coping with experiences of racism, reducing PrEP stigma, and providing education on HIV risk. In accordance with the MPowerment model, In collaboration with the PI, the BSMM core group and volunteers would lead the development, implementation, and evaluation of all intervention events. Both peer leaders and the primary investigator (all BSMM) will collaborate to develop specific events (M-Groups), guided by the findings in both the quantitative and qualitative studies. M-Groups will be held once every month. Events will be 2 hour in-person activities focused on the aforementioned goals.
Study: NCT05802563

Intervention type: DEVICE
Intervention: fitness tracker
Description: Study subjects will wear a Fitbit fitness tracker
Study: NCT05159921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to an automated conversational agent (SurgInfoBot)
Description: See above under arm/group descriptions.
Study: NCT05604014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Health Coach
Description: My Health Coach is a self-directed mobile health intervention for adults with FASD. It is grounded in self-determination theory and integrates well-established behavior change strategies. It has a cloud-based infrastructure and uses a just-in-time adaptive intervention design and a simple and engaging chatbot interface. It provides adults just the right type and amount of support, when they are most receptive.
Study: NCT05594355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEBOFORTAN
Description: TEBOFORTAN 240 mg is administrated 1 tablet per day
Study: NCT05553938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Description: Empagliflozin 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Description: Empagliflozin 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Empagliflozin matched placebo tablet
Study: NCT06385210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi structured interviews
Description: Participants will be interviewed concerning perceived barriers to routine surgical video recording
Study: NCT05730218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONL1204 Ophthalmic Solution
Description: ONL1204 Ophthalmic Solution at one of two doses delivered via intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONL1204 Ophthalmic Solution
Description: ONL1204 Ophthalmic Solution at one of two doses delivered via intravitreal injection

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Sham injection is performed by touching the eye surface with a syringe without a needle
Study: NCT05604287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID119031166M
Description: The participants will receive a single oral dose of ID119031166M or once daily oral doses of ID119031166M for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID119031166M
Description: The participants will receive a single oral dose of ID119031166M or once daily oral doses of ID119031166M for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participant will receive a oral dose of Placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participant will receive a oral dose of Placebo.
Study: NCT04430335

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone interview
Description: Interested participants will complete a telephone interview to determine eligibility for the study. If found to be eligible for the study, participants will be registered and set up a time to speak with an assigned study coach.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy
Description: Participants will speak with their assigned coach over the phone for 12 weeks to discuss the cognitive behavioral therapy (CBT) study workbook and provide feedback. CBT is a type of treatment that teaches people different ways to handle anxiety and/or depressive symptoms, such as by relaxing the body, changing thoughts, and solving problems. Participants will receive a workbook focused on teaching these strategies.
Study: NCT05313893

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine
Description: Subjects receive two doses of quadrivalent influenzavaccine administered 4 weeks apart by intramuscularinjection. Each 0.5-ml dosecontained 15 μg of hemagglutinin per strain.
Study: NCT04530825

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait-List Control
Description: -Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PREVENT Tool
Description: -PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese adolescent patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
Study: NCT06342310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RE104 for Injection
Description: Single, subcutaneous dose of RE104 for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RE104 for Injection
Description: Single, subcutaneous dose of RE104 for Injection
Study: NCT04833309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pharmacopuncture therapy
Description: The procedure will be implemented to participants twice a week for total 5 weeks. The specific prescription including type and dosage will be determined according to the physician's choice, and information will be recorded in the case report form retrospectively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: The procedure will be implemented to participants twice a week for total 5 weeks. The specific prescription including type and body part will be determined according to the physician's choice, and information will be recorded in the case report form retrospectively.
Study: NCT05351736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Treatment with lurasidone
Study: NCT05907928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scotchbond universal adhesive plus
Description: New generation BPA free universal adhesive

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single bond Universal
Description: Radiolucent universal adhesive
Study: NCT05765435

Intervention type: OTHER
Group type: OTHER
Intervention: 12-week exercise and walking program
Description: The exercise program requires isometric quadriceps contractions in a supine position with a rolled-up towel placed behind the knee. The exercise program will be performed by participants 5 days per week for 12 weeks. The walking program will be performed 3 days per week for 12 weeks. Participants will walk for 10 minutes and then gradually increase walking time to 30 minutes by the end of the study. Participants will wear the device during the exercise and walking program, which may range from 1 minute to 35 minutes per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-week exercise and walking program
Description: The exercise program requires isometric quadriceps contractions in a supine position with a rolled-up towel placed behind the knee. The exercise program will be performed by participants 5 days per week for 12 weeks. The walking program will be performed 3 days per week for 12 weeks. Participants will walk for 10 minutes and then gradually increase walking time to 30 minutes by the end of the study. Participants will wear the device during the exercise and walking program, which may range from 1 minute to 35 minutes per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-week exercise and walking program
Description: The exercise program requires isometric quadriceps contractions in a supine position with a rolled-up towel placed behind the knee. The exercise program will be performed by participants 5 days per week for 12 weeks. The walking program will be performed 3 days per week for 12 weeks. Participants will walk for 10 minutes and then gradually increase walking time to 30 minutes by the end of the study. Participants will wear the device during the exercise and walking program, which may range from 1 minute to 35 minutes per day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES
Description: Sleeve applies neuromuscular stimulation during exercises to help contract appropriate muscles at appropriate times.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES
Description: Sleeve applies neuromuscular stimulation during exercises to help contract appropriate muscles at appropriate times.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES
Description: Sleeve applies functional electrical stimulation as patients walk to help contract appropriate muscles at appropriate times.
Study: NCT05620862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome
Description: In phase Ia, mitoxantrone hydrochloride liposome will be administered by an intravenous infusion at three doses of 16 mg/m2, 20 mg/m2 and 24 mg/m2 . In phase Ib, mitoxantrone hydrochloride liposome will be administered by an intravenous infusion of 24mg/m2. Up to 6 cycles (21 days per cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 50mg/ m2，d1-5, 21 days per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.5mg/ m2，d1 , 21 days per cycle
Study: NCT06496243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
Description: 10 mg obicetrapib for 8 weeks followed by 10 mg obicetrapib/ 140 mg evolocumab (every 2 weeks) combination for 8 weeks
Study: NCT06542237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YCT-529
Description: In the Phase 1b part of the study, 4 dosing cohorts and one optional 5th cohort with 4 participants will be evaluated (up to 20 participants): 15, 45, 90 and 180 mg. In the Phase 2a part, up to 3 cohorts of up to 10 participants (up to 30 participants) will receive doses within the range of doses that was well tolerated and had biological activity in the Phase 1b portion.
Study: NCT05865652

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy
Description: Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy
Description: Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy
Study: NCT04869683

Intervention type: OTHER
Group type: OTHER
Intervention: description of MDS pzatient cohort
Description: description of MDS patient cohort
Study: NCT05608837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCS-01
Description: One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCS-01
Description: One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCS-01
Description: One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCS-01
Description: One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study.
Study: NCT06188468

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: standard-of-care imaging (18F-FDG, 68Ga-PSMA, or 68Ga-DOTATATE PET/CT), 68Ga-MY6349 PET/CT
Description: Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceuticals (18F-FDG, 68Ga-PSMA, or 68Ga-DOTATATE) and 68Ga-MY6349, and undergoes PET/CT imaging within the specified time.
Study: NCT04850144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Monohydrate
Description: Tiotropium Easyhaler 10 µg/dose Product variant D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Monohydrate
Description: Tiotropium Easyhaler 10 µg/dose Product variant E

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Monohydrate
Description: Tiotropium Easyhaler 10 µg/dose Product variant F

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Monohydrate
Description: Tiotropium Easyhaler 10 µg/dose Product variant F

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Monohydrate
Description: Tiotropium Easyhaler 10 µg/dose Product variant G

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Monohydrate
Description: Tiotropium Easyhaler 10 µg/dose Product variant H

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium Bromide Monohydrate
Description: Spiriva 18 µg/capsule inhaled via Handihaler
Study: NCT03733678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for SARCs
Description: SARCs are offered free to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for SARCs
Description: SARCs are offered free to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for SARCs
Description: SARCs are offered free to the client
Study: NCT04850144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Easyhaler with oral activated charcoal
Description: The charcoal suspension will be administered orally with Tiotropium Easyhaler 10 µg/dose Product variant F
Study: NCT03318952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: A buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed of 2% lidocaine with 1:100,000 epinephrine will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: A buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed of 2% lidocaine with 1:100,000 epinephrine will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: articaine
Description: A single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: articaine
Description: A single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered